Jan 31 2011
Erchonia, pioneer in low intensity laser healthcare solutions, has declared the results of a pilot study on the capability of low-intensity lasers to decrease the harmful side-effects of radiation treatment for cancer-affected persons.
With intense cancer therapies, about 80% of patients are bearing adverse toxicity and approximately 50% of them are suffering from adverse side effects. Such issues make the patients to stop the treatment before the course completion.
The pilot study evaluated the efficiency of an Erchonia low-intensity laser against these severe problems. All patients who underwent the low-intensity laser therapy experienced a considerable relief in oral mucositis, pain and dermatitis induced by radiation treatment. Erchonia will conclude the results through a clinical trail, which will be carried out in 2011 and intends to obtain the FDA clearance in 2012.
Kansas-based Via Christi Medical Center’s oncologist, David Bryant executed the pilot study using the Erchonia laser device on cancer patients suffering from severe pain. After several laser treatments, patients, who were reluctant to undergo the radiation therapy, completed their full course of treatment.